Quick Answer
AYTU BIOPHARMA, INC reported Net Income Loss of -$13.56 million for the year ending 2025.
- AYTU BIOPHARMA, INC showed an increase of +14.4% in Net Income Loss from 2024 to 2025.
- This data is from AYTU BIOPHARMA, INC's annual report (Form 10-K), filed with the SEC on September 23, 2025.
- XBRL data for this metric is available from 2006 to 2025 (20 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2015: -$2.28 million | Q4 2015: -$3.33 million | Q1 2016: -$7.27 million | Q3 2016: -$5.72 million | Q4 2016: -$4.82 million | Q1 2017: -$5.22 million | Q3 2017: -$4.25 million | Q4 2017: -$3.67 million | Q1 2018: -$2.82 million | Q3 2018: -$3.45 million | Q4 2018: -$4.66 million | Q1 2019: -$4.50 million | Q3 2019: -$4.93 million | Q4 2019: -$214.2 thousand | Q1 2020: -$5.33 million | Q3 2020: -$4.31 million | Q4 2020: -$9.53 million | Q1 2021: -$25.46 million | Q3 2021: -$27.85 million | Q4 2021: -$11.55 million | Q1 2022: -$53.29 million | Q3 2022: -$701.0 thousand | Q4 2022: -$6.69 million | Q1 2023: -$7.20 million | Q3 2023: -$8.12 million | Q4 2023: -$220.0 thousand | Q1 2024: -$2.89 million | Q3 2024: $1.47 million | Q4 2024: $788.0 thousand | Q1 2025: $3.99 million | Q3 2025: $1.97 million | Q4 2025: -$10.58 million.
- Over the full 20 years of available data (2006 to 2025), AYTU BIOPHARMA, INC's Net Income Loss has declined by 19,153.0%.
- Historical annual values: Fiscal year 2025: -$13.56 million | Fiscal year 2024: -$15.84 million | Fiscal year 2023: -$17.05 million | Fiscal year 2022: -$108.78 million | Fiscal year 2021: -$58.29 million | Fiscal year 2020: -$13.62 million | Fiscal year 2019: -$27.13 million | Fiscal year 2018: -$10.19 million | Fiscal year 2017: -$22.51 million | Fiscal year 2016: -$28.18 million | Fiscal year 2015: -$7.72 million | Fiscal year 2014: -$5.58 million | Fiscal year 2013: -$57.3 thousand | Fiscal year 2012: -$59.7 thousand | Fiscal year 2011: -$136.8 thousand | Fiscal year 2010: -$60.3 thousand | Fiscal year 2009: -$58.9 thousand | Fiscal year 2008: -$57.2 thousand | Fiscal year 2007: -$49.0 thousand | Fiscal year 2006: -$70.4 thousand.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: